VR
VRTX
Market ClosedVertex Pharmaceuticals Incorporated
US
6.10K employees
CEO: Reshma Kewalramani
Founded: 1991
$451.63
+$0.00(+NaN%)
Market Cap
114.63B
Beta
0.31
52W Range
N/A
Dividend Yield
0.00%
Forecasting Analysis
AI-powered predictions and statistical risk modeling for short-term price movements
AI Insight:
AI short-term forecasts for Vertex Pharmaceuticals are trending marginally higher, indicating limited near-term momentum. Analyst consensus shows strong coverage with a moderate spread, suggesting broad alignment on a positive outlook. This combination reflects a balanced risk profile with an opportunity for steady gains.
Current Price
N/A
Last closing price
Price Prediction
Machine learning prediction based on historical price patterns
Period:
Analyst Price Target for VRTX
Loading analyst price targets...
Wall Street Forecasts
Revenue Forecast
Past Growth
N/A
Based on Historical CAGR
Forward Growth
N/A
Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
Revenue Analysis
Comparison of Actual and Estimated Revenues
Loading chart data...
Revenue growth steady at 0.0%.
Operating Profitability Forecast
Past Growth
N/A
EBITDA Historical CAGR
Forward Growth
N/A
EBITDA Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
EBITDA Analysis
Comparison of Actual and Estimated EBITDA
Loading chart data...
EBITDA maintaining 0.0% trajectory.
Earnings Per Share Forecast
Past Growth
N/A
EPS Historical CAGR
Forward Growth
N/A
EPS Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
EPS Analysis
Comparison of Actual and Estimated Earnings Per Share
Loading chart data...
EPS growth stable around 0.0%.
Explore VRTX
VRTX in the Healthcare
Large Cap